[{"data":1,"prerenderedAt":239},["ShallowReactive",2],{"drug-rotigotine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":74,"contraindications":122,"warnings":132,"renal":146,"monitoring":147,"interactions":148,"review":149,"examples":152,"atc":166,"iran":168,"usApproval":180,"links":186,"populations":203},"rotigotine",1,{"fa":7,"en":8},"روتیگوتین","Rotigotine","nervous-system",{"fa":11,"en":12},"آگونیست دوپامین (پچ)","Dopamine agonist (patch)",[14],{"name":15,"market":16},"Neupro","US",[18,19,7],"neupro","نوپرو",[21,35,43,51,59,66],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"patch-2","patch","transdermal","2 mg\u002F24 h patch",{"amount":27,"unit":28,"perUnit":29},2,"mg","application",[16],[32],{"source":33,"section":34},"fda-neupro","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"patch-4","4 mg\u002F24 h patch",{"amount":39,"unit":28,"perUnit":29},4,[16],[42],{"source":33,"section":34},{"id":44,"form":23,"route":24,"label":45,"concentration":46,"markets":48,"refs":49},"patch-6","6 mg\u002F24 h patch",{"amount":47,"unit":28,"perUnit":29},6,[16],[50],{"source":33,"section":34},{"id":52,"form":23,"route":24,"label":53,"concentration":54,"markets":56,"refs":57},"patch-8","8 mg\u002F24 h patch",{"amount":55,"unit":28,"perUnit":29},8,[16],[58],{"source":33,"section":34},{"id":60,"form":23,"route":24,"label":61,"concentration":62,"markets":63,"refs":64},"patch-1","1 mg\u002F24 h patch",{"amount":5,"unit":28,"perUnit":29},[16],[65],{"source":33,"section":34},{"id":67,"form":23,"route":24,"label":68,"concentration":69,"markets":71,"refs":72},"patch-3","3 mg\u002F24 h patch",{"amount":70,"unit":28,"perUnit":29},3,[16],[73],{"source":33,"section":34},[75,100,110],{"id":76,"disease":77,"label":78,"population":81,"type":85,"unit":28,"dose":86,"refs":87,"notes":90},"early","parkinsons",{"fa":79,"en":80},"پارکینسون مراحل اولیه — شروع پچ ۲ mg\u002F۲۴ ساعت؛ هفتگی ۲ mg افزایش تا ۶ mg\u002F۲۴ ساعت","Early-stage Parkinson disease — start 2 mg\u002F24 h patch; increase by 2 mg weekly to 6 mg\u002F24 h",{"minAge":82},{"value":83,"unit":84},18,"year","fixed",{"perDose":27,"perDoseMax":47,"dosesPerDay":5},[88],{"source":33,"section":89},"2.1",[91],{"text":92,"refs":95},{"fa":93,"en":94},"روزانه یک پچ روی پوست سالم (شکم، ران، باسن، پهلو، شانه، بازو)؛ محل هر روز عوض شود. قطع تدریجی: حداکثر ۲ mg هر روز در میان.","One patch daily on intact skin (abdomen, thigh, hip, flank, shoulder, upper arm); rotate the site daily. Taper: max 2 mg every other day.",[96,98],{"source":33,"section":97},"2.3",{"source":33,"section":99},"2.4",{"id":101,"disease":77,"label":102,"population":105,"type":85,"unit":28,"dose":107,"refs":108},"adv",{"fa":103,"en":104},"پارکینسون پیشرفته — شروع ۴ mg\u002F۲۴ ساعت؛ هفتگی ۲ mg افزایش تا ۸ mg\u002F۲۴ ساعت","Advanced-stage Parkinson disease — start 4 mg\u002F24 h; increase by 2 mg weekly to 8 mg\u002F24 h",{"minAge":106},{"value":83,"unit":84},{"perDose":39,"perDoseMax":55,"dosesPerDay":5},[109],{"source":33,"section":89},{"id":111,"disease":112,"label":113,"population":116,"type":85,"unit":28,"dose":118,"refs":119},"rls","restless-legs",{"fa":114,"en":115},"سندرم پای بی‌قرار — شروع ۱ mg\u002F۲۴ ساعت؛ هفتگی ۱ mg افزایش تا ۳ mg\u002F۲۴ ساعت","Restless legs syndrome — start 1 mg\u002F24 h; increase by 1 mg weekly to 3 mg\u002F24 h",{"minAge":117},{"value":83,"unit":84},{"perDose":5,"perDoseMax":70,"dosesPerDay":5},[120],{"source":33,"section":121},"2.2",[123],{"id":124,"severity":125,"text":126,"refs":129},"hyper","block",{"fa":127,"en":128},"حساسیت به روتیگوتین یا اجزای پچ.","Hypersensitivity to rotigotine or the patch components.",[130],{"source":33,"section":131},"4",[133,140],{"text":134,"refs":137},{"fa":135,"en":136},"به خواب رفتن ناگهانی حین فعالیت روزانه؛ توهم؛ افت فشار و سنکوپ؛ رفتار تکانشی و وسواسی (قمار، خرید)؛ دیسکینزی؛ تب و گیجی با قطع ناگهانی.","Falling asleep during daily activities; hallucinations; hypotension and syncope; impulse-control\u002Fcompulsive behaviours (gambling, shopping); dyskinesia; hyperpyrexia and confusion on abrupt withdrawal.",[138],{"source":33,"section":139},"5",{"text":141,"refs":144},{"fa":142,"en":143},"حساسیت به سولفیت؛ افزایش فشار و ضربان؛ تشدید (augmentation) در RLS؛ پیش از MRI یا کاردیوورژن پچ برداشته شود (سوختگی)؛ گرما روی پچ نه.","Sulfite sensitivity; increased blood pressure and heart rate; augmentation in RLS; remove before MRI or cardioversion (burns); no heat over the patch.",[145],{"source":33,"section":139},[],[],[],{"status":150,"reviewer":151,"date":151},"unverified",null,[153,158,162],{"regimen":76,"formulation":22,"input":154,"expect":157},{"ageYears":155,"weightKg":156},60,75,{"perDose":27,"tabletsPerDoseRounded":5,"upperPerDose":47},{"regimen":101,"formulation":36,"input":159,"expect":161},{"ageYears":160,"weightKg":156},65,{"perDose":39,"tabletsPerDoseRounded":5,"upperPerDose":55},{"regimen":111,"formulation":60,"input":163,"expect":165},{"ageYears":164,"weightKg":156},50,{"perDose":5,"tabletsPerDoseRounded":5,"upperPerDose":70},[167],"N04BC09",{"status":169,"forms":170,"refs":175},"registered",[171],{"code":172,"en":173,"fa":174},"50757","ROTIGOTINE PATCH TRANSDERMAL 13.5 mg\u002F30cm2","پچ پوستی روتیگوتین ۱۳٫۵ میلی‌گرم \u002F ۳۰ سانتی‌متر ۲",[176],{"source":177,"section":178,"url":179},"darooyab-generic","G-5520\u002FRotigotine","https:\u002F\u002Fwww.darooyab.ir\u002FG-5520\u002FRotigotine",{"kind":181,"refs":182,"id":185},"NDA",[183],{"source":33,"section":184},"SPL approval \u002F marketing category","NDA021829",[187,190,194,198,201],{"kind":188,"url":189,"label":185},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=021829",{"kind":191,"url":192,"label":193},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=939e28c5-f3a9-42c0-9a2d-8d471d82a6e0","FDA Neupro",{"kind":195,"url":196,"label":197},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa607059.html","Rotigotine Transdermal Patch",{"kind":199,"url":200,"label":167},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N04BC09",{"kind":202,"url":179,"label":8},"darooyab",{"pregnancy":204,"lactation":213,"pediatric":221,"geriatric":230},{"level":205,"text":206,"quote":209,"refs":210},"caution",{"fa":207,"en":208},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate data on the developmental risk associated with the use of NEUPRO in pregnant women.",[211],{"source":33,"section":212},"8.1",{"level":205,"text":214,"quote":217,"refs":218},{"fa":215,"en":216},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of rotigotine in human milk, the effects of rotigotine on the breastfed infant, or the effects of rotigotine on milk production.",[219],{"source":33,"section":220},"8.2",{"level":222,"text":223,"quote":226,"refs":227},"not-established",{"fa":224,"en":225},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients for any indication have not been established.",[228],{"source":33,"section":229},"8.4",{"level":231,"text":232,"quote":235,"refs":236},"ok",{"fa":233,"en":234},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in plasma levels of rotigotine were observed between patients who were 65 to 80 years old compared with younger patients receiving the same rotigotine doses.",[237],{"source":33,"section":238},"8.5",1792191565467]